Michal Abraham

Jerusalem, JM 91120, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway.

BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway.

Journal: Research square
Published: March 04, 2025

Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFNγ-dependent PD-L1.

Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFNγ-dependent PD-L1.

Journal: Frontiers in immunology
Published: September 26, 2024

CDC25C Protein Expression Correlates with Tumor Differentiation and Clinical Outcomes in Lung Adenocarcinoma.

CDC25C Protein Expression Correlates with Tumor Differentiation and Clinical Outcomes in Lung Adenocarcinoma.

Journal: Biomedicines
Published: December 13, 2022

CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression.

CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression.

Journal: Journal of hematology & oncology
Published: June 06, 2022

BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.

BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.

Journal: Cancer
Published: August 02, 2020

Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance.

Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance.

Journal: Bone marrow transplantation
Published: October 29, 2019

The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.

The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.

Journal: Biochemical pharmacology
Published: May 14, 2019

Promiscuous Chemokine Antagonist (BKT130) Suppresses Laser-Induced Choroidal Neovascularization by Inhibition of Monocyte Recruitment.

Promiscuous Chemokine Antagonist (BKT130) Suppresses Laser-Induced Choroidal Neovascularization by Inhibition of Monocyte Recruitment.

Journal: Journal of immunology research
Published: January 07, 2019

Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.

Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.

Journal: Cytokine
Published: October 06, 2017

Development of Novel Promiscuous Anti-Chemokine Peptibodies for Treating Autoimmunity and Inflammation.

Development of Novel Promiscuous Anti-Chemokine Peptibodies for Treating Autoimmunity and Inflammation.

Journal: Frontiers in immunology
Published: August 02, 2017

Matrix metalloproteinase 12 promotes tumor propagation in the lung.

Matrix metalloproteinase 12 promotes tumor propagation in the lung.

Journal: The Journal of thoracic and cardiovascular surgery
Published: March 17, 2017

Natural and induced immunization against CCL20 ameliorate experimental autoimmune encephalitis and may confer protection against multiple sclerosis.

Natural and induced immunization against CCL20 ameliorate experimental autoimmune encephalitis and may confer protection against multiple sclerosis.

Journal: Clinical immunology (Orlando, Fla.)
Published: February 19, 2017
Showing 1-12 of 24

Last Updated: 09/26/2026